Characteristic Glycemic Patterns during Capivasertib Treatment Identified by Continuous Glucose Monitoring.

We herein report a case of hyperglycemia in a patient with recurrent breast cancer treated with the AKT inhibitor capivasertib. Continuous glucose monitoring revealed a distinctive pattern characterized by pronounced daytime postprandial hyperglycemia and nocturnal-to-morning decline, which resolved during the drug-free intervals. Hyperglycemia was unresponsive to metformin treatment but was markedly exacerbated by intravenous glucose infusion. These findings suggest that capivasertib-induced hyperglycemia is caused by an impaired glucose uptake and dysregulated hepatic glucose output associated with AKT inhibition. Careful glycemic monitoring and individualized management are necessary in patients receiving AKT inhibitors.